AD VISE

YOUR OBSERVATIONAL RINVOQ STUDY

STEP-BY-STEP

Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)

AD VISE

To learn more about the AD-VISE study, please visit **www.clinicaltrials.gov** and search for "**NCXXXX**"

"There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something better tomorrow."

– Orison Swett Marden

AbbVie has patients at heart

patients at heart
PATIENTSATHEART.COM

Patients at Heart was created specifically to support and inform clinical trial patients and the people in their support networks, as well as anyone interested in joining a clinical trial in Canada.

abbvie

ABOUT AD-VISE

PREPARE & GET STARTED

ONGOING TREATMENT ACTIVITIES

NOTES

AD-VISE

REAL-WORLD UTILIZATION OF UPADACITINIB IN ADULT AND ADOLESCENT PATIENTS LIVING WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD-VISE)

AD-VISE is an observational study that was developed to see how well RINVOQ® (upadacitinib) works in real life and its impact on moderate to severe atopic dermatitis. During the next 2 years (24 months), your study doctor and staff will collect information about your health, your atopic dermatitis, and your quality of life during your routine care appointments.

The main goals of this study are to observe how physicians utilize RINVOQ and to observe the effectiveness of RINVOQ in treatment of moderate to severe atopic dermatitis over a 2-year follow-up period in routine practice.

This tool is meant to help walk you through your RINVOQ treatment initiation and the AD-VISE study, step by step. It combines all your activities from the start of treatment with RINVOQ and your activities within the AD-VISE study.

NOTE This may not represent your exact pathway.

BASED ON THE TIMING OF YOUR DOCTOR'S OWN ROUTINE VISIT SCHEDULE, THE STUDY WILL COLLECT THE FOLLOWING INFORMATION*:



BASELINE ASSESSMENTS

The baseline visit is your starting point in the study. Once you have signed the informed consent form the following first steps will be covered:

- Review of the study's eligibility criteria
- Demographics (age, gender, etc.)
- Review of your medical history, including a review of your past and current treatments and vaccinations
- Review of your atopic dermatitis history, including prior and current treatments
- Standard medical activities and evaluations, including your current atopic dermatitis presentation
- Questionnaires regarding your current disease activity and quality of life

ACTIVITY LEGEND

Patient Questionnaires

Evaluation of your general health, current AD treatment, AD presentation, routine evaluations, and patient questionnaires

Discussions with your doctor and/or study team

*It is possible that your doctor may see you only at some or all of these timepoints, based on your doctor's own routing visit schedule.

NOTE
All patients will be followed for 2 years (24 months) whether you continue your treatment with RINVOQ or not, as long as you do not withdraw your consent.

THE COMPLETION OF THE QUESTIONNAIRES ARE ESSENTIAL TO THE OUTCOME OF THE STUDY
The collection of routine evaluations as requested by your doctor will also be used for this study.

Contact the study team:

North York Research Inc. - Dr. Firouzeh Niakosari, MD FRCPC

Maryam Moazzami

Email: maryam@bnderm.com

Tel: 416-222-2204

abbvie